172 related articles for article (PubMed ID: 25501462)
21. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
22. The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies.
Pleštilová L; Mann H; Andrés Cerezo L; Pecha O; Vencovský J; Šenolt L
Arthritis Res Ther; 2014 Oct; 16(5):468. PubMed ID: 25359220
[TBL] [Abstract][Full Text] [Related]
23. Cardiac and skeletal muscle scintigraphy in dermato- and polymyositis: clinical implications.
Buchpiguel CA; Roizemblatt S; Pastor EH; Hironaka FH; Cossermelli W
Eur J Nucl Med; 1996 Feb; 23(2):199-203. PubMed ID: 8925856
[TBL] [Abstract][Full Text] [Related]
24. Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis.
Zhang L; Zhou H; Peng Q; Jiang W; Qiao W; Wang G
Int J Rheum Dis; 2017 Feb; 20(2):252-260. PubMed ID: 26891180
[TBL] [Abstract][Full Text] [Related]
25. [
Sun L; Dong Y; Zhang N; Lv X; Chen Q; Wei W
Exp Ther Med; 2018 Jun; 15(6):5023-5028. PubMed ID: 29805526
[TBL] [Abstract][Full Text] [Related]
26. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity.
Suzuki F; Kubota T; Miyazaki Y; Ishikawa K; Ebisawa M; Hirohata S; Ogura T; Mizusawa H; Imai T; Miyasaka N; Nanki T
Arthritis Res Ther; 2012 Mar; 14(2):R48. PubMed ID: 22394569
[TBL] [Abstract][Full Text] [Related]
27. A potential clinical usefulness of measuring serum bilirubin levels in patients with polymyositis.
Peng YF; Zhang L; Pan GG; Wei YS
Eur Rev Med Pharmacol Sci; 2016; 20(4):631-5. PubMed ID: 26957263
[TBL] [Abstract][Full Text] [Related]
28. Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis.
Raouf J; Idborg H; Englund P; Alexanderson H; Dastmalchi M; Jakobsson PJ; Lundberg IE; Korotkova M
Arthritis Res Ther; 2018 May; 20(1):83. PubMed ID: 29720222
[TBL] [Abstract][Full Text] [Related]
29. Dermatomyositis and polymyositis associated with the antiphospholipid syndrome-a novel overlap syndrome.
Sherer Y; Livneh A; Levy Y; Shoenfeld Y; Langevitz P
Lupus; 2000; 9(1):42-6. PubMed ID: 10713646
[TBL] [Abstract][Full Text] [Related]
30. Features of polymyositis and dermatomyositis in the elderly: a case-control study.
Pautas E; Chérin P; Piette JC; Pelletier S; Wechsler B; Cabane J; Herson S
Clin Exp Rheumatol; 2000; 18(2):241-4. PubMed ID: 10812498
[TBL] [Abstract][Full Text] [Related]
31. Epidemiologic analysis of the clinical features of Japanese patients with polymyositis and dermatomyositis.
Tomimitsu H; Ohta A; Nagai M; Nishina M; Ishihara S; Kohsaka H
Mod Rheumatol; 2016; 26(3):398-402. PubMed ID: 26375202
[TBL] [Abstract][Full Text] [Related]
32. Prognosis and mortality of polymyositis and dermatomyositis patients.
Airio A; Kautiainen H; Hakala M
Clin Rheumatol; 2006 Mar; 25(2):234-9. PubMed ID: 16477398
[TBL] [Abstract][Full Text] [Related]
33. Cardiac function in patients with polymyositis or dermatomyositis: a three-dimensional speckle-tracking echocardiography study.
Zhong Y; Bai W; Xie Q; Sun J; Tang H; Rao L
Int J Cardiovasc Imaging; 2018 May; 34(5):683-693. PubMed ID: 29168054
[TBL] [Abstract][Full Text] [Related]
34. Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program.
Bertolucci F; Neri R; Dalise S; Venturi M; Rossi B; Chisari C
Eur J Phys Rehabil Med; 2014 Apr; 50(2):161-9. PubMed ID: 23820876
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
36. The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA.
Alexanderson H; Reed AM; Ytterberg SR
J Rheumatol; 2012 Nov; 39(11):2134-41. PubMed ID: 22942260
[TBL] [Abstract][Full Text] [Related]
37. Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis.
Martis N; Viau P; Zenone T; Andry F; Grados A; Ebbo M; Castela E; Brihaye B; Denis E; Liguori S; Audemard A; Schoindre Y; Morin AS; Terrier B; Marcq L; Mounier N; Lidove O; Chaborel JP; Quinsat D
Eur Radiol; 2019 Dec; 29(12):6708-6716. PubMed ID: 31250167
[TBL] [Abstract][Full Text] [Related]
38. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis.
Mammen AL
Ann N Y Acad Sci; 2010 Jan; 1184():134-53. PubMed ID: 20146695
[TBL] [Abstract][Full Text] [Related]
39. Increased osteopontin in muscle and serum from patients with idiopathic inflammatory myopathies.
Xiao F; Tan JZ; Xu X; Zhu BL; Fang S; Wang XF
Clin Exp Rheumatol; 2015; 33(3):399-404. PubMed ID: 25936410
[TBL] [Abstract][Full Text] [Related]
40. T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.
Houtman M; Ekholm L; Hesselberg E; Chemin K; Malmström V; Reed AM; Lundberg IE; Padyukov L
Arthritis Res Ther; 2018 Aug; 20(1):188. PubMed ID: 30157932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
